LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced a significant enhancement of its capabilities: a 50% expansion and an investment exceeding $2 million in its standalone offering for Analytical Testing Services (ATS) alongside the introduction of new suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio.
LGM Pharma unveils enhanced analytical testing services and expands CDMO portfolio with additional suppository manufacturing capabilities
- Thread starter Educator
- Start date